|Year : 2018 | Volume
| Issue : 3 | Page : 127-131
The association between the use of new oral contraceptive pills and periodontal health: A matched case–control study
Leena Smadi1, Aiman Zakaryia2
1 Department of Conservative Dentistry, Faculty of Dentistry, University of Jordan, Amman, Jordan
2 Consultant Gynecologist, Hope Fertility Clinic, Amman, Jordan
|Date of Web Publication||14-Jun-2018|
Dr. Leena Smadi
Faculty of Dentistry, University of Jordan, Queen Rania Street, Postal Code 111983, Amman
Source of Support: None, Conflict of Interest: None
Aim: The aim of this study was to evaluate the effects of oral contraceptive pills (OCPs) on the periodontal status of the women using them. Materials and Methods: During the period from January 2016 to June 2017, 139 oral contraceptive users (Group A) and 142 nonusers (Group B) were examined by a blinded examiner using a mouth mirror and a 15-mm conventional periodontal probe (Hu-Friedy). The dental examination included the simplified oral hygiene index (OHI-S), gingival index, sulcus bleeding index (SBI), and clinical attachment loss (CAL). A full-mouth examination excluding the third molars was performed at four sites per tooth (mesiobuccal, distobuccal, mesiolingual, and distolingual). The results of these examinations were compared between the two groups to identify significant differences. Results: Both groups were comparable with regard to their demographic data. Group A had a significantly higher mean OHI-S score than Group B (0.43 vs. 0.29, respectively). The gingival index score was also higher in OCP users than in nonusers (0.78 vs. 0.37, respectively). The SBI score was 0.72 in Group A and 0.41 in Group B, demonstrating a significant difference between OCP users and nonusers. The CAL score was 1.62 in Group A versus 1.11 in Group B, and this difference was statistically significant. Conclusions: The use of combined oral contraceptives can influence the periodontal condition of patients, resulting in increased gingival disease. This adverse effect can be enhanced by the use of newer generations of OCPs, especially in high-risk populations.
Keywords: Gingivitis, oral contraceptive pills, periodontal diseases
|How to cite this article:|
Smadi L, Zakaryia A. The association between the use of new oral contraceptive pills and periodontal health: A matched case–control study. J Int Oral Health 2018;10:127-31
|How to cite this URL:|
Smadi L, Zakaryia A. The association between the use of new oral contraceptive pills and periodontal health: A matched case–control study. J Int Oral Health [serial online] 2018 [cited 2022 Jan 28];10:127-31. Available from: https://www.jioh.org/text.asp?2018/10/3/127/234518
| Introduction|| |
Oral contraceptives have been used as a means of contraception for a long time, and millions of women have used them over the last 60 years. The use of oral contraceptives is associated with small, but serious increased risks of thromboembolic and cardiovascular complications  and minor side effects, including gingival and/or periodontal disease.
The effects of sex steroids on the gingiva and periodontal status have been described by many studies that have demonstrated that endogenous sex steroid hormones play significant roles in modulating periodontal tissue responses and may alter the periodontal tissue responses to microbial plaque, thereby directly contributing to periodontal disease. Sex steroids can influence the periodontium during different life stages including puberty, menstruation, pregnancy, menopause, and postmenopause. The effect of oral contraceptives on gingival diseases has been described by many authors over the years,,, although the compositions and dosages of sex steroids in modern oral contraceptives pills (OCPs) have shifted toward higher progestogenic doses and lower estrogenic doses. Therefore, we conducted this cross-sectional, comparative study to examine the effects of new generation of oral contraceptives on the gingival status of the women using them.
| Materials and Methods|| |
During the period from January 2016 to June 2017, we recruited 139 women aged between 18 and 39 years who were using combined oral contraceptive (COC) pills from among the women attending a gynecology clinic at the Islamic Hospital. For the control group, we recruited 142 women who were not current users of OCPs and had not used them during the previous year. Ethical approval was granted from the Ethical Committee of the Islamic Hospital Ethical Board (Ethical approval number IHEB 17–138), and informed consent forms were signed by all women who enrolled in the study; all informed consent was in Arabic although a translated copy to English was available for patients on requests. The inclusion criteria for the participating women were at least 1 year of continued use of combined pills and at least 24 teeth (except for third molars).
The exclusion criteria were as follows: pregnancy or delivery within 12 months before data collection; drug or alcohol abuse; history of radiotherapy or chemotherapy in the past 5 years; early or premature menopause; breastfeeding; the presence of any systemic condition that could influence the host response to plaque accumulation (e.g., diabetes mellitus); periodontal treatment, including professional prophylaxis, within the 6-month period before data collection; and the use of drugs that could induce gingival enlargement (e.g., calcium channel blockers, cyclosporine, or anticonsultants).
A detailed questionnaire was completed by all patients included in the study that collected their full medical history and COC intake before the clinical examination. The test group volunteers were questioned about the name, dose, and total length of uninterrupted use of COCs, which were recorded in the patient's record.
The periodontal status of the patients was evaluated by a single-blinded examiner using a mouth mirror and a 15-mm conventional periodontal probe (Hu-Friedy). The dental examination included simplified oral hygiene index (OHI-S), gingival index (GI), sulcus bleeding index (SBI), and clinical attachment loss (CAL). A full-mouth examination excluding the third molars was performed at four sites per tooth (mesiobuccal, distobuccal, mesiolingual, and distolingual).
The Kruskal–Wallis or Fisher's exact test was used to compare the median or mean values for the patient characteristics and the outcomes related to the in vitro fertilization (IVF) treatment. Student's t-test with Bonferroni correction or one-way ANOVA was used to compare two or more mean values of the indices before and after IVF. Statistical analyses were conducted using SPSS version 18 software (PASW ®, IBM, Chicago, USA). The level of statistical significance of all comparisons was set at 5% (P ≤ 0.05).
| Results|| |
A total of 376 women were interviewed for enrollment, including 273°CP users and 203 nonusers. Of the women interviewed, 141 of the OCP users fulfilled the inclusion criteria, but two of them opted to withdraw from the study after their initial acceptance, resulting in data from a total of 139 OCP users.
In the control group, 147 women fulfilled the inclusion criteria, but five of them opted to withdraw from the analysis, resulting in 142 women enrolled in the control group (Group B). Flowchart 1 demonstrates the inclusion process [Figure 1].
Both groups were comparable, with no significant differences in age, weight, previous pregnancies, previous use of OCP 1 year or more before their enrollment in the study, or medical diseases necessitating medical treatment apart from the diseases mentioned in the exclusion criteria [Table 1].
[Table 2] lists the type and composition of OCPs used by the women in Group A, showing that 38.9% of OCP users use the newer generation of OCP with higher progestogen affinity while 41.7% use two different products in which the progesterone has a spironolactone analog effect.
The average duration of use of OCP by Group A was 2.3 ± 0.4 years. The Pearson's correlation coefficient was used to test the effect of duration of use of OCP on periodontal indexes. [Table 3] demonstrates the results of this analysis. For the control group, the same test was used to demonstrate the effect of age of women on the periodontal indexes; the results are shown in [Table 4].
|Table 3: Correlation between age, total duration of oral contraceptive therapy, and clinical periodontal parameters in test group|
Click here to view
|Table 4: Correlation between age and clinical periodontal parameters in control group|
Click here to view
OCP users had a significantly higher mean OHI-S score than nonusers (0.43 vs. 0.29, respectively). The GI score was also higher in OCP users compared to nonusers, with a GI index of 0.78 in Group A compared to 0.37 in Group B. The SBI score was 0.72 in Group A compared to 0.41 in Group B, showing a significant difference between OCP users and nonusers. CAL was 1.62 in Group A versus 1.11 in Group B, and this difference was statistically significant. [Table 5] demonstrates these findings.
|Table 5: Periodontal status parameters among oral contraceptive users and nonusers|
Click here to view
| Discussion|| |
Our results were in accordance with the findings from previous similar studies, in which Kalkwarf, as early as 1978, reported an increased gingival inflammatory index score in OCP users. Tilakaratne et al. found an increased risk of gingival disease, as expressed by an increase in the mean GI score, in OCP users compared to nonusers in Sri Lankan women. In 2010, two studies showed similar results of increased GI scores in OCP users compared to nonusers., The study by Haerian-Ardakani et al. showed an increase in the mean GI score, pocket depth, and attachment loss in oral contraceptive users compared to nonoral contraceptive users.
Domingues et al., in a 2011 report, demonstrated both increased probing depth and increased SBI scores in OCP users compared to nonusers.
On the other hand, there were a few studies failed to demonstrate an increased risk of gingival disease in OCP users. Arumugam et al. reported nonsignificant differences in the mean GI scores, mean probing depths, and mean clinical attachment levels between contraceptive users and nonusers.
Knight  reported a nonsignificant difference in the mean GI scores between contraceptive users and nonusers, but they showed a greater loss of attachment in women who had used OCPs for more than 1.5 years compared to those who had taken oral contraceptives for a shorter period.
Our study confirmed the effect of the duration of OCP use on the gingival diseases parameters, showed by other studies which demonstrate an increase in disease with a longer duration of OCP use.,,,,
Our study included more patients in both groups than all other previous studies, which enhance the significance of our study.
In our study, the effect of OCP use on gingival disease was significant after only 1 year of use, which can be explained by the fact that the Jordanian population might be at higher risk for the development of periodontal diseases. This enhanced predisposition for periodontal disease should explain the similarity between our results and the results from underdeveloped countries such as Sri Lanka and Iraq.,
Both estrogen and progesterone have receptors on the gingiva., Estrogen receptors are also found on periosteal fibroblasts, scattered fibroblasts of the lamina propria, and periodontal ligament fibroblasts and osteoblasts, resulting in complex effects that enhance the probability of gingival and periodontal changes in women exposed to either endogenous sex steroids such as during puberty and pregnancy or exogenous sex steroids such as those resulting from the use of OCP. This effect has been demonstrated clinically, and a positive correlation has been identified between estradiol and progesterone serum levels and GI inflammation in many clinical situations, including pregnancy, puberty, infertility treatment, and even during menstrual cycles.,,,
The effect of the sex steroids in OCPs will not only manifest direct effects on the gingiva the periosteum or the fibroblasts but will also significantly increase the Bacteroides species in the oral cavities of OCP users, incidence of localized osteitis, and variation in the coagulation and fibrinolytic factors, leading to a greater incidence of clot lysis.
Despite the lower doses of estrogen in the newer generations of OCP (20–30 μg compared to 50 μg in older generations of ethinylestradiol), the effects of the sex steroids in OCPs are still evident. The results in our study may be unequivocal to the results of previous studies because the progesterone component in the current OCPs has a more pronounced progestogen effect than in the older generations in which the progesterone component had more androgenic effect [Table 2].
Androgens may play a significant role in the maintenance of bone mass and may inhibit osteoclastic functions, inhibit prostaglandin synthesis, and reduce interleukin-6 production during inflammation. Testosterone also stimulates bone cell proliferation and differentiation and therefore has a positive effect on bone metabolism and enhances matrix syntheses by periodontal ligament fibroblasts and osteoblasts.
This study demonstrates possible effect of type of hormones used in OCP on oral health effect of the drug, raising possible future research opportunities looking at the effect of type of progesterone on the oral health, including progesterone used in other types or routes of contraception such as injectable, patches, or intrauterine. Such studies may include as well other hormone-dependent diseases which may necessitate the use of progesterone-like treatment of polycystic diseases. The studies until now looked at the effect of hormonal changes of the disease on oral health but did not investigate the effect of hormonal therapy which includes both androgen and progesterone.
| Conclusions|| |
Our results suggest that the use of COCs can influence the periodontal conditions of patients, resulting in increased gingival disease. This adverse effect can be enhanced by the use of newer generations of OCPs that lack the possible protective effect of the androgenic properties of older OCPs, especially in high-risk populations.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Shukla A, Jamwal R. Adverse effect of combined oral contraceptive pills. Asian J Pharm Clin Res 2017;10:17-21.
Preshaw PM. Oral contraceptives and the periodontium. Periodontol 2000 2013;61:125-59.
Markou E, Eleana B, Lazaros T, Antonios K. The influence of sex steroid hormones on gingiva of women. Open Dent J 2009;3:114-9.
Mahajan A, Sood R. Case report: Oral contraceptives induced gingival overgrowth – A clinical case report. POJ Dent Oral Care 2017;1:1-5.
Pankhurst CL, Waite IM, Hicks KA, Allen Y, Harkness RD. The influence of oral contraceptive therapy on the periodontium – Duration of drug therapy. J Periodontol 1981;52:617-20.
Saini R, Saini S, Sharma S. Oral contraceptives alter oral health. Ann Saudi Med 2010;30:243.
] [Full text]
Ahuja M, Ahuja M, Pujari P. Ultra-low-dose oral contraceptive pill: A new approach to a conventional requirement. Int J Reprod Contracept Obstet Gynecol 2017;6:364-70.
Greene JC, Vermillion JR. The simplified oral hygiene index. J Am Dent Assoc 1964;68:7-13.
Löe H. The gingival index, the plaque index and the retention index systems. J Periodontol 1967;38 Suppl 6:610-6.
Mühlemann HR, Son S. Gingival sulcus bleeding – a leading symptom in initial gingivitis. Helv Odontol Acta 1971;15:107-13.
Clark DC, Chin Quee T, Bergeron MJ, Chan EC, Lautar-Lemay C, de Gruchy K, et al.
Reliability of attachment level measurements using the cementoenamel junction and a plastic stent. J Periodontol 1987;58:115-8.
Kalkwarf KL. Effect of oral contraceptive therapy on gingival inflammation in humans. J Periodontol 1978;49:560-3.
Tilakaratne A, Soory M, Ranasinghe AW, Corea SM, Ekanayake SL, de Silva M, et al.
Effects of hormonal contraceptives on the periodontium, in a population of rural Sri-Lankan women. J Clin Periodontol 2000;27:753-7.
Sambashivaiah S, Rebentish PD, Kulal R, Bilichodmath S. The influence of oral contraceptives on the periodontium. J Health Sci 2010;1:1.
Haerian-Ardakani A, Moeintaghavi A, Talebi-Ardakani MR, Sohrabi K, Bahmani S, Dargahi M, et al.
The association between current low-dose oral contraceptive pills and periodontal health: A matched-case-control study. J Contemp Dent Pract 2010;11:033-40.
Domingues RS, Ferraz BF, Greghi SL, Rezende ML, Passanezi E, Sant'Ana AC, et al.
Influence of combined oral contraceptives on the periodontal condition. J Appl Oral Sci 2012;20:253-9.
Arumugam M, Seshan H, Hemanth B. A comparative evaluation of subgingival occurrence of Candida
species in periodontal pockets of female patients using hormonal contraceptives and non-users – A clinical and microbiological study. Oral Health Dent Manag 2015;14:206-11.
Knight GM, Wade AB. The effects of hormonal contraceptives on the human periodontium. J Periodontal Res 1974;9:18-22.
Ababneh KT, Abu Hwaij ZM, Khader YS. Prevalence and risk indicators of gingivitis and periodontitis in a multi-centre study in North Jordan: A cross sectional study. BMC Oral Health 2012;12:1.
Abd-Ali EH, Shaker NT. The effect of oral contraceptive on the oral health with the evaluation of Salivary IgA and Streptococcus mutans
in some Iraqi women. Marietta Daily J 2013;10:52-63.
Vittek J, Munnangi PR, Gordon GG, Rappaport SC, Southren AL. Progesterone “receptors” in human gingiva. IRSC Med Sci 1982;10:381-4.
Vittek J, Hernandez MR, Wenk EJ, Rappaport SC, Southren AL. Specific estrogen receptors in human gingiva. J Clin Endocrinol Metab 1982;54:608-12.
Darshana Nair S, Varma S, Suragimath G, Zope S, Kale V, Abbayya K. Prevalence of periodontal disease in women with polycystic ovary syndrome – A comparative descriptive study. J Evol Med Dent Sci 2017;6:4733-6.
Machtei EE, Mahler D, Sanduri H, Peled M. The effect of menstrual cycle on periodontal health. J Periodontol 2004;75:408-12.
Miyazaki H, Yamashita Y, Shirahama R, Goto-Kimura K, Shimada N, Sogame A, et al.
Periodontal condition of pregnant women assessed by CPITN. J Clin Periodontol 1991;18:751-4.
Smadi L. Gingival and periodontal changes in patients undergoing in vitro
fertilization treatment: A clinical study. Indian J Dent Res 2017;28:650-4.
] [Full text]
Thomas KE. Association of anaerobic bacteria in sub gingival plaque and oral health of women. Eur J Pharm Med Res 2016;3:654-63.
Aronson JK. Meyler's Side Effects of Drugs. 16th
ed. Elsevier Science, Netherland ; 2016.
Sweet JB, Butler DP. Increased incidence of postoperative localized osteitis in mandibular third molar surgery associated with patients using oral contraceptives. Am J Obstet Gynecol 1977;127:518-9.
Dulani K. Postmenopausal women: Oral problems and management, a review. Med J Obstet Gynecol 2016;4:1088.
Güncü GN, Tözüm TF, Cağlayan F. Effects of endogenous sex hormones on the periodontium – Review of literature. Aust Dent J 2005;50:138-45.
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5]
|This article has been cited by|
||Oral Microflora, in Cases with Gingival Hypertrophy Caused by Fixed Orthodontic Appliances
| ||Ilma Robo, Saimir Heta, Enxhi Gjumsi, Vera Ostreni |
| ||SN Comprehensive Clinical Medicine. 2021; |
|[Pubmed] | [DOI]|
||Is the use of contraceptives associated with periodontal diseases? A systematic review and meta-analyses
| ||Micaele Maria Lopes Castro, Maria Karolina Martins Ferreira, Iasmin Encaua Essashika Prazeres, Paula Beatriz de Oliveira Nunes, Marcela Baraúna Magno, Cassiano Kuchenbecker Rösing, Lucianne Cople Maia, Rafael Rodrigues Lima |
| ||BMC Women's Health. 2021; 21(1) |
|[Pubmed] | [DOI]|